Press release
Adrenoleukodystrophy Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, by DelveInsight | Autobahn Therapeutics, Viking Therapeutics, SwanBio Therapeutics
"Adrenoleukodystrophy Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/adrenoleukodystrophy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Adrenoleukodystrophy Market.
The Adrenoleukodystrophy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Adrenoleukodystrophy Pipeline Report:
*
Companies across the globe are diligently working toward developing novel Adrenoleukodystrophy treatment therapies with a considerable amount of success over the years.
*
Adrenoleukodystrophy companies working in the treatment market are Autobahn Therapeutics, Viking Therapeutics, SwanBio Therapeutics, Poxel SA, Minoryx Therapeutics, and others, are developing therapies for the Adrenoleukodystrophy treatment
*
Emerging Adrenoleukodystrophy therapies such as - ABX-002, VK0214, SBT101, PXL065, PXL770, Leriglitazone (MIN102), and others are expected to have a significant impact on the Adrenoleukodystrophy market in the coming years.
Adrenoleukodystrophy Overview
Adrenoleukodystrophy (ALD) is a rare genetic disorder that affects the adrenal glands, the nervous system, and the myelin sheath of nerve cells in the brain. It primarily affects males and is caused by mutations in the ABCD1 gene located on the X chromosome.
Get a Free Sample PDF Report to know more about Adrenoleukodystrophy Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/adrenoleukodystrophy-pipeline-insight [https://www.delveinsight.com/report-store/adrenoleukodystrophy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Emerging Adrenoleukodystrophy Drugs Under Different Phases of Clinical Development Include:
*
ABX-002: Autobahn Therapeutics
*
VK0214: Viking Therapeutics
*
SBT101: SwanBio Therapeutics
*
PXL065: Poxel SA
*
PXL770: Poxel SA
*
Leriglitazone : Minoryx Therapeutics
*
OP101 : Orpheris
*
Leriglitazone (MIN102): Minoryx Therapeutics
Route of Administration
Adrenoleukodystrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Molecule Type
Products have been categorized under various Molecule types, such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Adrenoleukodystrophy Pipeline Therapeutics Assessment
*
Adrenoleukodystrophy Assessment by Product Type
*
Adrenoleukodystrophy By Stage and Product Type
*
Adrenoleukodystrophy Assessment by Route of Administration
*
Adrenoleukodystrophy By Stage and Route of Administration
*
Adrenoleukodystrophy Assessment by Molecule Type
*
Adrenoleukodystrophy by Stage and Molecule Type
DelveInsight's Adrenoleukodystrophy Report covers around 11+ products under different phases of clinical development like
*
Late-stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I)
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
*
Route of Administration
Further Adrenoleukodystrophy product details are provided in the report. Download the Adrenoleukodystrophy pipeline report to learn more about the emerging Adrenoleukodystrophy therapies [https://www.delveinsight.com/sample-request/adrenoleukodystrophy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key companies in the Adrenoleukodystrophy Therapeutics Market include:
Key companies developing therapies for Adrenoleukodystrophy are - AstraZeneca, Cipla Inc., Abbott, Bayer AG, Merck KGaA, GlaxoSmithKline plc, agtc, bluebird bio, MINORYX THERAPEUTICS SL, SwanBio Therapeutics, Inc., Viking Therapeutics, Novartis AG, Sanofi, Pfizer Inc., Sumitomo Corporation, Johnson & Johnson Private Limited, and others.
Adrenoleukodystrophy Pipeline Analysis:
The Adrenoleukodystrophy pipeline report provides insights into
*
The report provides detailed insights about companies that are developing therapies for the treatment of Adrenoleukodystrophy with aggregate therapies developed by each company for the same.
*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Adrenoleukodystrophy Treatment.
*
Adrenoleukodystrophy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
Adrenoleukodystrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Adrenoleukodystrophy market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Adrenoleukodystrophy drugs and therapies [https://www.delveinsight.com/sample-request/adrenoleukodystrophy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Adrenoleukodystrophy Pipeline Market Drivers
*
Increasing awareness towards genetic diseases coupled with genetic counseling, rise in the number of R&D activities are some of the important factors that are fueling the Adrenoleukodystrophy Market.
Adrenoleukodystrophy Pipeline Market Barriers
*
However, high cost of the treatment, side effects associated with the treatment and other factors are creating obstacles in the Adrenoleukodystrophy Market growth.
Scope of Adrenoleukodystrophy Pipeline Drug Insight
*
Coverage: Global
*
Key Adrenoleukodystrophy Companies: Autobahn Therapeutics, Viking Therapeutics, SwanBio Therapeutics, Poxel SA, Minoryx Therapeutics, and others
*
Key Adrenoleukodystrophy Therapies: ABX-002, VK0214, SBT101, PXL065, PXL770, Leriglitazone (MIN102), and others
*
Adrenoleukodystrophy Therapeutic Assessment: Adrenoleukodystrophy current marketed and Adrenoleukodystrophy emerging therapies
*
Adrenoleukodystrophy Market Dynamics: Adrenoleukodystrophy market drivers and Adrenoleukodystrophy market barriers
Request for Sample PDF Report for Adrenoleukodystrophy Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/adrenoleukodystrophy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1
Adrenoleukodystrophy Report Introduction
2
Adrenoleukodystrophy Executive Summary
3
Adrenoleukodystrophy Overview
4
Adrenoleukodystrophy- Analytical Perspective In-depth Commercial Assessment
5
Adrenoleukodystrophy Pipeline Therapeutics
6
Adrenoleukodystrophy Late Stage Products (Phase II/III)
7
Adrenoleukodystrophy Mid Stage Products (Phase II)
8
Adrenoleukodystrophy Early Stage Products (Phase I)
9
Adrenoleukodystrophy Preclinical Stage Products
10
Adrenoleukodystrophy Therapeutics Assessment
11
Adrenoleukodystrophy Inactive Products
12
Company-University Collaborations (Licensing/Partnering) Analysis
13
Adrenoleukodystrophy Key Companies
14
Adrenoleukodystrophy Key Products
15
Adrenoleukodystrophy Unmet Needs
16
Adrenoleukodystrophy Market Drivers and Barriers
17
Adrenoleukodystrophy Future Perspectives and Conclusion
18
Adrenoleukodystrophy Analyst Views
19
Appendix
20
About DelveInsight
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=adrenoleukodystrophy-pipeline-update-2024-fda-approvals-therapeutic-advancements-by-delveinsight-autobahn-therapeutics-viking-therapeutics-swanbio-therapeutics]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Adrenoleukodystrophy Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, by DelveInsight | Autobahn Therapeutics, Viking Therapeutics, SwanBio Therapeutics here
News-ID: 3558727 • Views: …
More Releases from ABNewswire
Country Creek Animal Hospital Strengthens Veterinarian Support in Allen, TX, Ext …
Country Creek Animal Hospital continues to support pet owners across Allen and Frisco by focusing on dependable care, consistent service coverage, and community-centered values. Through thoughtful growth and operational improvements, Country Creek Animal Hospital remains dedicated to providing reliable veterinary support that meets local needs while maintaining the trust of the families it serves.
Introduction: Expanding Vet Clinic Support in Allen, TX
Country Creek Animal Hospital continues to reinforce its role as…
Kids Dentist in Las Vegas and Centennial Offers Pain-Free, Needle-Free Laser Den …
Desert Kids Dental, led by pediatric dentist Dr. Sandra Thompson, is redefining the dental experience for children in Centennial and Las Vegas by offering advanced Solea Registered Laser dentistry, a modern technology designed to deliver truly pain-free and needle-free dental care. As a trusted Kids Dentist serving local families, Desert Kids Dental continues to focus on comfort, efficiency, and positive experiences for children of all ages.
For many children and parents…
UK Taxpayers Turn to the Best App for Filing Taxes as Digital Submissions Surge …
As HMRC continues to support online interactions, app-based filing is becoming standard practice across the UK. The shift reflects a wider move toward self-service financial tools that prioritise usability, transparency, and speed. Pie's product strategy centres on making tax approachable and human, reinforcing its proposition: It's your money. Claim it.
LONDON, United Kingdom - February 23, 2026 - UK taxpayers are increasingly relying on mobile apps to manage and submit their…
How to Find Reputable Gold Dealers and Avoid Scams in 2026
Image: https://www.abnewswire.com/upload/2026/02/47e5b4ef7e33f72e2f9ac00f352f35cf.jpg
Investing in physical gold is a time-honored strategy for wealth preservation and hedging against economic uncertainty. However, the integrity of your investment depends entirely on the trustworthiness of your dealer. In 2026, the digital landscape is fraught with both industry leaders and sophisticated scammers.
To protect your capital and ensure the authenticity of your gold, you must know how to find reputable gold dealers [https://sdbullion.com/gold] and identify the red flags…
More Releases for Adrenoleukodystrophy
Adrenoleukodystrophy (ALD) Market Opportunities in 2034
Market Overview
The Adrenoleukodystrophy (ALD) Market is growing steadily as improvements in newborn screening, genetic diagnostics, and awareness of rare neurodegenerative disorders lead to earlier detection and clinical intervention.
ALD is a genetically inherited X-linked disorder caused by mutations in the ABCD1 gene, leading to the toxic accumulation of very long-chain fatty acids (VLCFAs) in the brain, adrenal glands, and spinal cord. The condition manifests in multiple forms, including childhood cerebral…
Adrenoleukodystrophy Treatment Market: Transforming Rare Disease Therapeutics
The adrenoleukodystrophy treatment market was valued at approximately USD 1.1 billion in 2023 and is anticipated to reach around USD 2.4 billion by 2033, growing at a CAGR of 8.1% from 2024 to 2033.
The adrenoleukodystrophy (ALD) treatment market represents a critical segment within the rare disease therapeutics landscape, addressing one of the most challenging genetic disorders affecting the nervous system and adrenal glands. This X-linked genetic condition, caused by mutations…
X Linked Adrenoleukodystrophy Market Regional Analysis & Global Forecast to 2025 …
The X-Linked Adrenoleukodystrophy Market Is Set To Grow At An Estimated CAGR Of 14% From 2025 To 2034, Rising From $1.2 Billion In 2024 To $4.5 Billion By 2034.
On April 15, 2025, Exactitude Consultancy., Ltd. released a research report offers a comprehensive examination of the various processes and materials used in the production of X Linked Adrenoleukodystrophy market goods. The market study excludes key regions that are accelerating marketization. This…
X-linked Adrenoleukodystrophy Pipeline Therapeutics Assessment Report 2024 (Upda …
DelveInsight's, "X-Linked Adrenoleukodystrophy Pipeline Insight, 2024," report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in X-Linked Adrenoleukodystrophy (X-ALD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in X-linked adrenoleukodystrophy Research. Learn more…
Adrenoleukodystrophy Pipeline Outlook, Clinical Trials, FDA Approvals, and Compa …
DelveInsight's, "Adrenoleukodystrophy Pipeline Insight 2024" report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in the Adrenoleukodystrophy pipeline landscape. It covers the Adrenoleukodystrophy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Adrenoleukodystrophy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Adrenoleukodystrophy Pipeline Report
• DelveInsight's Adrenoleukodystrophy pipeline…
Adrenoleukodystrophy Pipeline, FDA Approvals, Clinical Trials Developments and C …
DelveInsight's, "Adrenoleukodystrophy Pipeline Insight, 2023," report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in the Adrenoleukodystrophy pipeline landscape. It covers the Adrenoleukodystrophy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Adrenoleukodystrophy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Adrenoleukodystrophy Pipeline Report
• DelveInsight's Adrenoleukodystrophy…
